



#7
O3CO

Docket No. 60807-A-PCT-US/JPW/GJG/CSN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Alexander Gad et al.
Serial No. : 09/816,989
Filed : March 23, 2001
For : COPOLYMER 1 RELATED POLYPEPTIDES FOR USE AS
MOLECULAR WEIGHT MARKERS AND FOR THERAPEUTIC
USE

#7

1185 Avenue of the Americas
New York, New York 10036
December 21, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

**COMMUNICATION IN RESPONSE TO OCTOBER 22, 2001 NOTICE TO COMPLY
WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

This Communication is submitted in response to an October 22, 2001 Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures issued by the United States Patent and Trademark Office in connection with the above-identified application. A response to the October 22, 2001 Notice is due December 22, 2001. Accordingly, this Communication is being timely filed.

The October 22, 2001 Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures indicates that a copy of the "Sequence Listing" in computer readable form has been submitted. However, the Notice alleges that the content of the computer readable form does not comply with the requirements of 37 C.F.R. §1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." The Notice stated that applicants must provide a

Applicant : Alexander Gad et al.
Serial No. : 09/816,989
Filed : March 23, 2001
Page : 2

substitute computer readable form (CFR) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR §1.825(b). Applicants attach hereto a copy of the Notice as **Exhibit A**.

In response, applicants have corrected the typographical error in sequence 6, section <231> as suggested. Support for the correcting the description of Artificial Sequence from "Synthetic P" to "Synthetic Peptide" may be found, *inter alia*, on page 13, lines 25-27 and page 14, lines 5-15. Applicants submit as **Exhibit B** hereto substitute sheets of the "Sequence Listing." Applicants also submit a computer readable form (CFR) copy of the substitute sheets of the "Sequence Listing." In addition, applicants submit as **Exhibit C** hereto a Statement in Accordance with 37 C.F.R. §1.825(b), certifying that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) "Sequence Listing" and includes no new matter. The Statement in Accordance with 37 C.F.R. §1.825(b) (**Exhibit C**) also certifies that the substitute sheets of the "Sequence Listing" include no new matter.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone the number provided below.

Applicant : Alexander Gad et al.
Serial No. : 09/816,989
Filed : March 23, 2001
Page : 3


No fee is deemed necessary in connection with the filing of this Communication. If any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231



John P. White
Reg. No. 28,678

12/21/01
Date